Enhanced Portfolio, Ease of Partnership
Created in 2019 by four European-based pharmaceutical companies, Aggrega Pharma is focused on enhancing
our partners portfolios by providing access to the most attractive generic drug product opportunities.
About
Aggrega Pharma is committed to building a selective, valuable pipeline of generic products by leveraging the vast R&D, clinical and manufacturing experience and capabilities of its members. The shareholders are 4 European companies:
-
Bluepharma (Portugal)
-
Rafarm (Greece)
-
Substipharm (France)
-
Welding (Germany)
_e.jpg)
Vision
Establish Aggrega Pharma as a premier partner to create a fully integrated pharmaceutical supply chain up to commercialization of drug product.
Strategy
Invest in Aggrega’s internal drug product portfolio through
utilizing Aggrega’s global development, financial strength,
and scale in sourcing and manufacturing footprint.
Partner using flexible commercial models to co-develop
and co-invest in generic drug products and select 505(b)2 opportunities.
Focus initially on US market and appropriately expand
concept ex-US.
Partnership
We are continually looking to expand and increase our finished dose portfolio through collaborative working – a core principle at Aggrega Pharma.
Our partnership combines flexible and innovative business models with collaborative process development to strengthen your products, while reducing your risk.
Our partnership offering is supported by our network of development and commercial manufacturing facilities
at Bluepharma (Portugal) and Rafarm (Greece) as well as our network of finished dose CDMOs in Europe, North America
and Asia to meet your global product requirements.
PORTUGAL
GERMANY
FRANCE
GREECE
Shareholders
Combined Revenue
>$500M/Year
Combined Employees
>1200
Countries
60+
Global Product Launches
100+
Headquarters
Coimbra, Portugal
Hamburg, Germany
Paris, France
Athens, Greece
Founded
2001
1955
1995
1976
Extended and Immediate Release
Oral Solid finished dose development and commercial manufacturing facilities (FDA inspected). Clinical study management expertise through Blueclinical.
Develop, register, supply
and commercialize drug
products globally with focus
on various dosage forms, incl. niche, complex & high potent.
API sourcing, regulatory affairs & distribution.
Develop, supply
and commercialize
drug products (ex-US) with
focus on niche, complex
dosage forms.
Sterile Injectable and Ophthalmic finished dose development and commercial manufacturing facilities (FDA inspected).
Team
Sérgio Paulo Simões
Board Member
![MITSOPOULOS_PHOTO[1].jpg](https://static.wixstatic.com/media/21c15b_b423020c5fd5452495d8cc37727b3e37~mv2.jpg/v1/crop/x_0,y_0,w_3000,h_2943/fill/w_175,h_172,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/MITSOPOULOS_PHOTO%5B1%5D.jpg)
Aris Mitsopoulos
Board Member
Lars Hallmayer
Board Member
Leopold Berthier
Board Member
Giulia Falcone
Executive Director
Tobias Silva
Executive Director
Simon Knölk
Executive Director
Portfolio
ER Oral Solid
Oral Thin Film
Complex Ophthalmic Suspension
High Potent Oral Solid
High Potent Oral Solid
Complex Nasal Spray
Sterile Ophthalmic Emulsion
Succinylcholine Injectable
Penicillamine Capsules
Ephedrine Injectable
On Deck*
In Development
ANDA Submission
Approved/
Commercial
IR Oral Solid
IR Oral Solid
Ophthalmic Ointment
* Early Development
Contact
Follow Us On:
© 2021 Proudly created with Wix.com
6 Arrow RD, STE 200
Ramsey, New Jersey 07446, USA